External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home 2021 ASCO Annual Meeting
Roche and Genentech at

2021 ASCO Annual Meeting

June 04 - June 08
Virtual
am.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Highlights
Coming soon
09:00 AM
Duration 12mins Virtual
Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab▼ in patients with recurrent or metastatic cervical cancer
Italiano A, Verlingue L, Prenen H, Guerra Alia EM, Tosi D, Perets R, Lugowska I, Moiseenko V, Gumus M, Arslan C, Lindsay CR, Dejardin D, Boetsch C, Kraxner A, Richard M, Evers S, Vardar T, Teichgräber V, Keshelava N, Dziadziuszko R
Oncology | Cervical Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 12mins Virtual
MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors
Meric-Bernstam F, Hainsworth J, Bose R, Burris H, Friedman C, Kurzrock R, Swanton C, Wang Y, Levy J, Price R, Schulze K, Patel A, Sweeney C
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:24 PM
Duration 15mins Virtual
Pooled analyses of immune-related adverse events (irAEs) and efficacy from the Phase 3 Trials IMpower130, IMpower132 and IMpower150
Socinski M, Jotte R, Cappuzzo F, Nishio M, Mok T, Reck M, Finley G, Yu W, Patel H, Paranthaman N, Bara I, West H
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:30 PM
Duration 12mins Virtual
The tumor microenvironment (TME) and atezolizumab▼ + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130
Emens L, Goldstein L, Schmid P, Rugo H, Adams S, Barrios C, Schneeweiss A, Diéras V, Iwata H, Chang C-W, Koeppen H, Chui S, Loi S, Molinero L
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:42 PM
Duration 12mins Virtual
Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) vs F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)
Lindeman GJ, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune SL, Armstrong A, Shannon C, Bertelli G, Fernando TM, Desai R, Gupta K, Hsu J, Crepelle-Fléchais A, Bardia A
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:00 AM
Duration 12mins Virtual
IMpower010: Primary Results of a Phase 3 Global Study of Atezolizumab▼ vs Best Supportive Care After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Wakelee HA, Altorki N, Zhou C, Csőszi T, Vynnychenko IO, Goloborodko I, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz BJ, Felip E
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 AM
Duration 11mins Virtual
Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab▼ in patients with non-small cell lung cancer: Results from the LCMC3 study
Dacic S, Travis W, Giltnane J, Abel J, Kos F, Hilz S, Fujimoto J, Sholl L, Khalil F, Ritter J, D'Apuzzo, Carbone D, Lee J, Rusch V, Johnson A, Schulze K, Kris M, Wistuba I
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

Sign up or login to unlock the full suite of MEDICALLY features
In-depth report: Genitourinary Cancer
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
In-depth report: Breast Cancer
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
In-depth report: Lung Cancer
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
In-depth report: Paediatric Oncology
Springer Healthcare
Open asset

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.